ANALYSISApril 13, 2026
Are pharmaceutical patents too long?
The U.S. Senate Judiciary Committee on April 3, 2025 advanced a bipartisan package of bills targeting pharmaceutical patent practices, including measures against patent thickets, product hopping, and pay-for-delay deals. The legislation reflects growing Congressional consensus that pharmaceutical companies are exploiting the patent system to extend drug monopolies well beyond the standard 20-year term. The 2025 patent cliff — in which several blockbuster drugs lose exclusivity — is intensifying the debate as brand-name manufacturers mount legal challenges to delay generic competition.
Pharmaceutical companies say long patents are the price of billion-dollar R&D bets that save lives — critics say those same patents are the reason Americans ration insulin and skip prescriptions. Who's right, and who pays if we get it wrong?
Not familiar with this story? Get context →
Pay-for-delay as patent abuse
C
Pay-for-delay is not a patent right — it is a brand manufacturer purchasing the suppression of the competition the patent system was designed to eventually produce. The 1790 bargain was temporary monopoly in exchange for public disclosure and eventual generic entry. When a company pays a rival to disappear, it is not exercising that bargain; it is voiding it.
L
We agree completely, and that agreement matters: you've just conceded the core reform case. If pay-for-delay 'voids the bargain,' then FTC enforcement against it and the Senate bills that target it are not attacks on property rights — they are enforcement of the terms under which those rights were granted.
C
Agreed on pay-for-delay, which is exactly why the Senate Judiciary package — backed by Cornyn and Grassley — targets that practice specifically rather than broadly auditing patent merit. The cautious, incremental approach a skeptic of regulatory overreach should prefer starts with the unambiguous abuse.
L
Then let's be clear about what's unambiguous: paying a competitor to stay off the market has no version that constitutes innovation, and building the reform case around that practice first is precisely the common ground this debate should start from.
Follow-on patents as systematic evergreening
C
The 78% figure is not an outlier — it is a pattern. When 78% of drugs associated with new patents are existing drugs, you are not looking at a system producing incremental improvements; you are looking at a systematic strategy of monopoly extension dressed in patent clothing. The Semaglutide timeline — 1993 to 2042, forty-nine years — is not the exception. It is the business model.
L
The conservative concern that follow-on patents sometimes reflect real improvements — extended-release formulations that improve adherence, for instance — has genuine intellectual weight. But Semaglutide collapses that argument: a drug that has already generated tens of billions in revenue does not need 29 additional years of protection beyond the original term to recoup R&D investment. At some point 'incremental improvement' becomes a legal fiction.
C
The Semaglutide case is damning precisely because the revenue numbers make the R&D justification implausible on its face — but the harder question is whether a regulatory body asked to make that call on every follow-on patent will get it right consistently, or occasionally chill genuine formulation research in the process.
L
That's a real concern, which is why starting with pay-for-delay and patent thickets — where no scientific judgment call is required — is the right sequencing. Semaglutide's 49-year span didn't require regulators to evaluate chemistry; it required someone to notice that the clock had been reset six times.
Fiscal scale of monopoly pricing
C
Branded drugs represent 9% of prescriptions but 84% of nearly $800 billion in total U.S. drug spending. Conservatives who care about entitlement sustainability cannot look at that ratio and call it a functioning market. Medicare and Medicaid are paying those prices — that is a fiscal problem with a market-structure cause, not a regulatory solution in search of a problem.
L
The 9%/84% ratio is striking, but the CBO projects the specific Senate bills save $3 billion over a decade — sobering against the scale of $800 billion in annual spending. That gap isn't an argument against reform; it's an argument that patent thickets are the lock, not the whole door, and that meaningful relief requires combining this with Medicare negotiating authority.
C
The $3 billion figure scores only the specific bills in a narrow window — generic entry historically reduces prices by 80-90%, and compounding savings from a market that stops being systematically gamed cannot be captured in a standard CBO scoring horizon. The modest near-term estimate argues for pairing measures, not for leaving the structure intact.
L
That's the honest case: patent reform is necessary but not sufficient, and pretending the Senate bills alone solve the $800 billion problem would be intellectually dishonest. The argument for passing them is that you cannot get to the rest of the solution without removing the lock first.
Hatch-Waxman's original market design
C
The Hatch-Waxman Act of 1984 was itself conservative market design — structured to reward genuine discovery while ensuring competition arrives on schedule. The Eliquis situation, where BMS and Pfizer are projected to collect over $50 billion in revenue that would otherwise have faced generic competition, is not the system working as designed. That $50 billion is a transfer from patients and taxpayers to shareholders enabled by legal maneuvering, not innovation.
L
You're right that Hatch-Waxman was designed to make competition arrive on schedule — which makes it worth noting that Congress already extended pharmaceutical exclusivity beyond the standard 20-year term through that act's restoration provisions. The industry has layered evergreening on top of an already-extended baseline, making the cumulative distortion worse than the raw patent term suggests.
C
Exactly — which is why the $50 billion Eliquis figure represents a double failure: the system granted extended terms through Hatch-Waxman's legitimate restoration provisions, then allowed patent thickets to extend exclusivity further still through procedures the act was never designed to enable.
L
A government-granted privilege that has been extended once legislatively and then gamed procedurally is not a free market — it is a cartel with increasingly elaborate paperwork, and restoring the Hatch-Waxman bargain means closing both routes to permanent monopoly.
Bipartisan reform as conservative legitimacy test
C
The Senate Judiciary package is backed by John Cornyn and Chuck Grassley — not exactly ideological revolutionaries. When conservatives with strong pro-business records conclude that patent thickets and pay-for-delay are indefensible, it signals that these practices cannot be sustained even on industry-friendly grounds. This is not price control. It is restoring the competitive market the patent bargain was always supposed to create.
L
The Cornyn-Grassley alignment is politically significant, but the real test is whether 'restoring competition' rhetoric translates into bills with teeth. Bipartisan agreement that the abuse is real has existed for years — the FTC has been challenging improper Orange Book listings since 2023. The question is whether Congress moves from consensus to statute before the next administration reverses the FTC's posture.
C
That urgency argument actually strengthens the case for codifying these reforms in statute rather than relying on agency enforcement that can be reversed with an administration change — which is precisely what the Senate Judiciary package does.
L
Agreed: durable reform requires statute, not agency posture, and a bipartisan Senate vote is the mechanism that makes it durable. The conservative framing — restoring the market rather than regulating it — is also the framing most likely to survive the next Congress.
Conservative's hardest question
The strongest challenge to this argument is the R&D investment problem: if follow-on patents genuinely fund the formulation research that makes drugs safer and more adherent-friendly, restricting them could reduce the pipeline of real improvements. The line between legitimate incremental innovation and evergreening is genuinely contested in courts, and a conservative should be cautious about trusting regulators to draw it correctly every time.
Liberal's hardest question
The CBO's $3 billion savings estimate over ten years for the actual Senate bills is sobering — it suggests that even well-designed targeted reforms produce incremental rather than transformative price relief, which undercuts the urgency framing and implies that patent reform alone cannot solve the drug pricing crisis without accompanying structural changes to Medicare negotiation authority and pricing regulation.
Both sides agree: Both sides accept that pay-for-delay settlements — where brand manufacturers pay generic competitors to stay off the market — represent an indefensible abuse that no serious definition of 'innovation incentive' can justify.
The real conflict: They disagree on a factual-interpretive question: whether the 78% follow-on patent figure reflects a systematic industry strategy of monopoly extension or a mix of genuine incremental improvements and abuse that regulators cannot reliably distinguish — a dispute about what the data actually demonstrates versus what it only suggests.
What nobody has answered: If generic entry historically reduces drug prices by 80-90%, why did decades of generic market growth fail to bend the overall drug spending curve — and what does that failure reveal about whether patent reform, even if perfectly executed, can address a pricing system that has found workarounds before?
Sources
- U.S. Senate Judiciary Committee markup proceedings, April 3, 2025
- Congressional Budget Office estimate on pharmaceutical patent reform legislation, 2024
- FTC Orange Book patent challenge actions, 2023–2025
- Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman), 1984
- CEPR research on patent term length and drug development incentives
- STAT News op-ed on pharmaceutical monopoly reform savings
- Reported analysis of Eliquis (BMS/Pfizer) patent extension revenue projections
- Semaglutide patent filing and expiration records cited in search results
- IRA (Inflation Reduction Act) Medicare drug negotiation provisions, 2022
- Search queries: 'pharmaceutical patent length debate 2025', 'Senate Judiciary Committee drug patent bills April 2025', 'evergreening patent thicket pharmaceutical', 'semaglutide Ozempic patent history', 'FTC Orange Book patent challenges', 'CBO pharmaceutical patent reform estimate', 'Hatch-Waxman patent term restoration', 'drug R&D cost estimates disputed', '2025 patent cliff blockbuster drugs'